Medical Cannabis for Crohn's & Colitis — Switzerland 2026
In inflammatory bowel disease (IBD), cannabinoids help with pain, appetite loss and diarrhoea. A fraction of standard consultation cost for members.
In Crohn's and ulcerative colitis, THC preparations (RCTs Naftali 2013, 2021) improve symptom scores, appetite, pain and quality of life — inflammatory markers (CRP, calprotectin) drop less consistently. Cannabis complements biologics/immunosuppressants. CannabisClub members: 50 CHF instead of 190.
What the studies show
Naftali 2013 (RCT, n=21, Crohn's): cannabis flower (THC 23 %) inhaled twice daily — 45 % clinical remission vs 10 % placebo.
Naftali 2021 (RCT, ulcerative colitis): CBD-rich oil over 8 weeks improves Mayo score and quality of life.
Preparations & dosing
Dronabinol 2.5–5 mg three times daily for abdominal pain, appetite loss, nausea.
CBD oil 10 % 25–75 mg/day in inflammatory activity and anxiety.
Save as a CannabisClub member
IBD follow-up requires regular checks. External consult 190 CHF, member 50 CHF flat — on 4 consults/year over 560 CHF saved.
Registration is free. Become a member now.
FAQ
Does cannabis replace my biologics?
No. Cannabis handles symptoms (pain, appetite, nausea). Disease-modifying effect lacks strong evidence — infliximab, adalimumab, ustekinumab remain standard.
What does CannabisClub membership save?
Consult 50 CHF instead of 190 CHF. On quarterly follow-up, 560 CHF/year. Registration free.
Does insurance cover cannabis for IBD?
Rarely — only in resistance after failure of multiple biologics. Art. 71a HIO agreement required.
Cannabis for Crohn's & Colitis — Prescription Switzerland 2026 (Members 50 CHF)